This interactive session gives you the opportunity to be part of the discussion, share your ideas and hear from your peers on their thoughts.

Among the key talking points to consider:

• To what extent do IPF and autoimmune-related ILDs represent distinct diseases versus different expressions of a shared fibrotic process, and what does that mean for how we classify and study them?
• Are we currently measuring true biological disease activity in fibrotic ILDs, or mainly late-stage damage, and how might emerging biomarkers change how we define progression and guide treatment?